Seres Therapeutics' financial moves, potential drug developments, and investment appeal for speculative buyers in the biotech ...

The majority of secondary and prolonged infections were bacterial (56% and 49%, respectively) or viral (29% and 44%, respectively). Malignancy, congenital immunodeficiency, early and persistent ...

A new study demonstrates that the combination of lenalidomide (Revlimid) and obinutuzumab (Gazyva) is effective and well-tolerated in treating relapsed indolent non-Hodgkin lymphoma (NHL).

SAINT study is currently investigating intravenous trabectedin plus ipilimumab and nivolumab in the first line for advanced ...

The ELECTRA trial found that the combination of elacestrant and abemaciclib was well-tolerated and showed promising clinical ...

The US FDA has approved Kisqali (ribociclib) for treating early-stage breast cancer in combination with hormone therapy. It ...

While infections pose a risk for morbidity and mortality among patients with MDS, more needs to be studied about the topic, ...

A drug approved for treating the blood cancer multiple myeloma may offer a safe and effective way to reduce the risk of severe nosebleeds from a rare but devastating bleeding disorder.

According to new research, 80% of patients with previously untreated or relapsed/refractory advanced-phase chronic myeloid leukemia (CML) -- including both accelerated or myeloid blast phases of the ...

Combining endocrine therapy with the dual HER2 blockade of trastuzumab and pertuzumab and the CDK4/6 inhibitor ribociclib ...

Phase II trial of the novel combination, decitabine, venetoclax, and ponatinib achieved bone marrow remission in 80% of ...

Nearly a year after Coherus BioSciences’ on-body injector for Udenyca was rejected over external production issues, a ...